

Edgar Filing: REPLIGEN CORP - Form 8-K

REPLIGEN CORP
Form 8-K
January 05, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 5, 2004

REPLIGEN CORPORATION

(Exact name of registration as specified in charter)

Delaware	0-14656	04-2729386
(State or other	(Commission	(IRS Employer
jurisdiction of	File Number)	Identification No.)
incorporation)		

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA	02453
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (781) 250-0111

(Former name or former address, if changed since last report.)

Item 5. Other Events.

On January 5, 2004, Repligen Corporation announced that its phase 3 study of secretin for autism failed to meet the study's dual primary endpoints and that development of secretin for schizophrenia would continue. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7. Financial Statement and Exhibits.

(c)	Exhibit No.	Exhibit
	-----	-----
	99.1	Press Release, dated January 5, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: REPLIGEN CORP - Form 8-K

REPLIGEN CORPORATION

Dated: January 5, 2004

By: /s/ Walter C. Herlihy

Walter C. Herlihy
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

Exhibit

99.1

Press Release, dated January 5, 2004